Cell and Gene Regulatory
-
The Body As A Bioreactor – The Execution
10/31/2026
Genomic medicine depends as much on infrastructure as on the therapies themselves. Distributed production, scalable processes, and evolving regulation shape whether these medicines reach patients.
-
AI In Informed Consent: What's Your Risk?
10/31/2026
The more an AI tool writes on its own, the more human review its output demands. Five categories of consent tools carry distinct risks and call for specific documentation.
-
What Makes A RABS Design Effective In Aseptic Manufacturing?
10/29/2026
Choosing among passive open, active open, and closed barrier configurations is only the first step. Airflow, equipment geometry, and intervention frequency determine whether a design protects the process.
-
5 Questions To Ask Before Selecting A High-Containment Isolator
10/29/2026
Containment performance alone does not settle isolator selection. Workflow fit, operator ergonomics, transfer and cleaning, and long-term operation each shape whether a system works in practice.
-
Process Development For Commercial Readiness: How Soon Is Too Soon?
10/29/2026
Clinical performance in cell and gene therapy has outpaced manufacturing readiness. Knowing when to lock a process, and how much analytical data is too much, shapes the path to commercialization.
-
An Incomplete Response: Will The FDA Finish What It Started With Real-Time CRLs?
10/28/2026
FDA’s real-time CRL releases face legal and operational hurdles. Could AI-assisted redaction make transparency faster and more consistent?
-
Successful Partnership Advances AML Program To Phase II/III
10/26/2026
See how strong collaboration rescued a stalled AML study, proved a safer approach to a proven drug class, and turned a Phase I/II partnership into a global Phase II/III trial.
-
Manufacturing Oncolytic Viruses: Where Complexity Demands Experience
10/23/2026
Dose, concentration, potency, purity, recovery, and cost are closely linked in oncolytic virus manufacturing. Learn why early alignment can prevent costly challenges.
-
Navigating Outsourced Pharmaceutical Testing Through Today's Geopolitical Uncertainty
10/22/2026
Geopolitical shocks are reshaping outsourced pharmaceutical testing. Learn how procurement teams can strengthen resilience and protect continuity.
-
From Laboratory To Launchpad: Japan's Cell And Gene Therapy Ecosystem Hits Its Stride
10/21/2026
Japan is emerging as a credible cell and gene therapy hub as regulation, manufacturing, and capital advance, despite gaps in funding, talent, risk culture, and language.